Navigation Links
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
Date:8/7/2008

NEW YORK, Aug. 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Monday, August 11, 2008 at 8:30 a.m. EDT to discuss the second quarter 2008 financial results. Michael S. Weiss, Chairman and Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call.

In order to participate in the conference call, please call 1-877-719-9788 (U.S.), 1-719-325-4769 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

The press release announcing our financial results for this period will be posted on the Company's website, http://www.keryx.com, prior to the call.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Contact: Lauren Fischer, +1-212-531-5965


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
4. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
5. Keryx Biopharmaceuticals Receives Nasdaq Notification
6. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
7. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
8. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
9. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
11. Keryx Biopharmaceuticals Announces Additions to Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... Yorba Linda, Ca (PRWEB) , ... April 25, 2017 , ... ... latest webinar in the series will explore the laboratory testing for DIC in order ... a serious hypercoagulable disorder which can occur in hospitalized patients resulting in a high ...
(Date:4/25/2017)... San Diego, CA (PRWEB) , ... April 25, ... ... (CRO) division of L3 Healthcare, is pleased to announce the company is now ... data management. The iMedNet software certification enables the company’s clinical research team ...
(Date:4/25/2017)... ... April 25, 2017 , ... Dr. Robert ... P.A. , proudly announced today that acclaimed physiatrist Matthew Terzella, MD, has joined ... 15, 2017. , Dr. Terzella completed his residency in Physical Medicine and Rehabilitation ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... Leaders of ... of Quorum, will be featured in multiple sessions at this week’s Association of ... emerging trends to best practices in clinical research. , "We are excited to present ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
Breaking Biology News(10 mins):